Johnson JD

ORCID: 0000-0002-5331-7461 · 1 paper in corpus

2025

The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer.

Molecular cancer therapeutics ·doi:10.1158/1535-7163.mct-25-0130

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor clinical outcome. There is a dire need for the development of new targeted therapies for TNBC. Midkine (MDK), a multifunctional cytokine/growth facto…